PAX5 and acute lymphoblastic leukemia: Recent studies have shown that PAX5 inactivation, most commonly due to deletion or point mutation, is a frequent occurrence in B‐progenitor cases of ALL and results in a corresponding loss or disruption of the PAX5 protein (Mullighan et al, 2007).